AstraZeneca starts Phase III program for asthma drug tralokinumab – Pharmaceutical Business Review

AstraZeneca starts Phase III program for asthma drug tralokinumab
Pharmaceutical Business Review
AstraZeneca has started the Phase III program for an investigational human monoclonal antibody tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by the company's global biologics research and …

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.